Novo reports 25.4% mean weight loss among early CagriSema responders

Key highlights
  • Early responders, defined as at least 5% weight loss by week 8, had mean observed weight loss of 25.4% at week 68, versus 17.8% for delayed responders.
  • Women were more likely to be early than delayed responders: 71.8% versus 59.5%.
  • At week 68, 73.1% on CagriSema reported meaningful physical-function improvement versus 49.1% on placebo.
  • CagriSema is investigational; Novo filed a US New Drug Application in December 2025, with an FDA decision expected in Q4 2026.

Weight-loss response

Two post hoc analyses of the phase 3 REDEFINE 1 trial of investigational CagriSema, a fixed-dose combination of cagrilintide and semaglutide, were presented at ObesityWeek 2026. Among participants receiving 2.4 mg/2.4 mg, 67.8% were early responders, defined as achieving at least 5% weight loss by week 8. Their mean observed weight loss at week 68 was 25.4%, compared with 17.8% among delayed responders, who had lost less than 5% by week 8. These on-treatment findings are post hoc and hypothesis-generating.

Patient-reported function and safety

At week 68, 73.1% of participants receiving CagriSema reported a meaningful improvement in physical function, compared with 49.1% receiving placebo. Meaningful improvement in psychosocial function was reported by 69.0% and 42.1%, respectively. The efficacy estimand assumes participants adhered to treatment.

Adverse events led to discontinuation in 5.9% of CagriSema participants and 3.5% of placebo participants. Gastrointestinal events occurred in 79.6% and 39.9%, respectively, and were mostly transient and mild to moderate. Novo filed a US New Drug Application for weight management in December 2025; an FDA decision is expected in Q4 2026. CagriSema is not approved in the United States.

Source: Novo Nordisk

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

6 June 2026
Novo Nordisk: semaglutide (Wegovy) post‑hoc data across cardiometabolic conditions

Post‑hoc analyses link semaglutide to lower OSA incidence, fewer asthma events, improved systolic BP, and liver and cardiometabolic improvements across SELECT, STEP, ESSENCE and OASIS trials.

14 November 2026
Novo reports 21% weight loss with lower-dose CagriSema in phase 3 trial

The 68-week REDEFINE 9 study compared two dose levels with placebo in 309 adults with overweight or obesity without diabetes.

20 October 2026
Novo’s CagriSema linked to ~25% weight loss in women in REDEFINE 1 post hoc analyses

Post hoc REDEFINE 1 analyses found once‑weekly cagrilintide/semaglutide produced large weight and waist‑circumference reductions across menopausal stages; main adverse events were gastrointestinal. FDA decision expected Q4 2026.

30 September 2026
Novo Nordisk CagriSema lowers food‑cue brain activity, cuts organ fat and shows bone‑marker reassurance

fMRI shows reduced ‘food noise’ and cravings; trials report major weight loss, reductions in abdominal/liver/pancreas fat and preliminary bone‑marker reassurance.

21 September 2026
Novo Nordisk: CagriSema outperforms tirzepatide 5 mg for weight loss

CagriSema 1.0/1.0 delivered greater weight loss than tirzepatide 5 mg and 21% vs 2% vs placebo in obesity trial; HbA1c reduction was non‑inferior. FDA decision expected Q4 2026.